DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Idarucizumab
Idarucizumab
Idarucizumab Reverses Dabigatran Anticoagulant Activity in Healthy Chinese Volunteers: a Pharmacokinetics, Pharmacodynamics, and Safety Study
Reversal of Oral Anticoagulation in Patients with Acute Intracerebral Hemorrhage Joji B
Current Awareness in Clinical Toxicology Editors: Damian Ballam Msc and Allister Vale MD
AHFS Pharmacologic-Therapeutic Classification System
Oral Anticoagulants
Geisinger Lewistown Hospital Published: March 25, 2019
RCEM NPIS Antidote Guideline Appx 1
September 2017 ~ Resource #330909
Estonian Statistics on Medicines 2016 1/41
Antidote List
Queensland Health List of Approved Medicines
VCMC-SPH Drug Formulary
Critical Medicines List (PDF 745KB)
FDA Listing of Established Pharmacologic Class Text Phrases January 2021
California Poison Control System
Idarucizumab (PRAXBIND) National Drug Monograph December 2015 VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives
Study Protocol
Impact of Idarucizumab and Andexanet Alfa on DOAC Plasma Concentration and Clotpro® Clotting Time: an Ex Vivo Spiking Study in a Cohort of Trauma Patients
Top View
ANTIDOTE CHART ***This Poster Is Not Intended for Individual Patient Care
Ez-Minutes Volume 13, Issue 4 August 2015
Antidotes & Anecdotes: Disclosure
COMPARISON of the WHO ATC CLASSIFICATION & Ephmra/Intellus Worldwide ANATOMICAL CLASSIFICATION
Iowa Poison Control Center
Current Evidence for Pharmacologic Reversal Using Direct Oral Anticoagulants: What’S
Drugs Eligible for Billing with C9399 Version: January 2021
CONCLUSION How Should Canadian Pharmacy Departments Utilize
Reversal of Doacs Breakthroughs and Their Aftermath
761025Orig1s000
Virginia DUR Quarterly Newsletter
Estonian Statistics on Medicines 2017 1/42
Aminophylline Infusion
2021 Antidote Survey
Intravenous Stroke Thrombolysis After Reversal Of
Clinical Controversies in DOAC Reversal
2020 Chargelisting
Antidote Stocking Guidelines for B.C
Hcpcs Description
ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2018
Poisons and Poisoning
Clinical Protocols for Oral Anticoagulant Reversal During High Risk Of
ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
ATC/DDD Classification WHO Drug Information Vol
Current Awareness in Clinical Toxicology Editors: Damian Ballam Msc and Allister Vale MD
Mustknow New Drugs
2021 Standard Charges N/ a = Not Applicable Revised 03/15/2021
New Anesthesia Drugs Already Here Or on the Horizon
New Drugs – Part I Scott King, Pharm.D
Office Director Memo
Medical Drug Prior Authorization List/External Posting Effective August 2021 Page 1 Last Updated 8/4/2021
Antidotes for Reversal of Direct Oral Anticoagulants
Mrx CLINICAL ALERT
Praxbind, INN-Idarucizumab
AHFS Pharmacologic-Therapeutic Classification System
FSHP 2017 ANNUAL MEETING New Drugs Disclosure Objectives New
Procedure Description Charge Amount 1302300005 ROOM MED
ISMP—Medication Safety Self Assessment ® for High-Alert
761025Orig1s000
RCEM/NPIS Antidote Guideline List
[Ehdsi V3.0.0-RC1] Ehealth DSI – Master Value Set Catalogue
761025Orig1s000
COMPARISON of the WHO ATC CLASSIFICATION & Ephmra/PBIRG ANATOMICAL CLASSIFICATION
NOAC Antidotes Who Were Taking Rivaroxaban Or Apixaban, Respectively
Creation of a Virtual Antidotes Network Between Pharmacy Departments of Catalan Hospitals
Nova Scotia Guideline for the Management of Patients on Vitamin K Antagonists Or Direct Oral Anticoagulants Utilizing Prothrombin Complex Concentrates
Critical Medicines Where Timeliness of Administration Is Crucial
Drugs Billed Under Miscellaneous Codes J3490, J3590, J9999 Or C9399 Prior Authorization Coverage Information
Vancomycin Dosing: from Trough to AUC/MIC
Idarucizumab, Rch
Ventura County Medical Center-Santa Paula Hospital Drug Formulary
Procedure Codedispense for Drug